Summary results of selected novel agents in relapsed Hodgkin lymphoma (HL).
| Agent . | Target . | route . | Phase . | N . | PR . | CR . | PR + CR . | 1st author . |
|---|---|---|---|---|---|---|---|---|
| HDACs indicates histone deacetylases; mTOR, mammalian target of rapamycin. | ||||||||
| SGN3014 | CD30 | IV | I/II | 15 | 0 | 0 | 0 (0%) | Bartlett |
| MDX06015 | CD30 | IV | II | 47 | 2 | 2 | 4 (8%) | Ansell |
| SGN3521 | CD30 | IV | I (q3 weeks) | 44 | 6 | 11 | 17 (39%) | Younes |
| SGN3522 | CD30 | IV | I (weekly) | 17 | 1 | 7 | 8 (47%) | Bartlett |
| MGCD0103117 | HDACs | Oral | II | 21 | 6 | 2 | 8 (38%) | Younes |
| Panobinostat118 | HDACs | Oral | I | 20 | 8 | 0 | 8 (40%) | DeAngelo |
| Panobinostat70 | HDACs | Oral | II | 27 | 4 | 1 | 5 (18%) | Younes |
| Vorinostat71 | HDACs | Oral | II | 25 | 1 | 0 | 1 (4%) | Kirshbaum |
| Lenalidomide110 | ? | Oral | II | 12 | 3 | 1 | 4 (33%) | Fehniger |
| Lenalidomide111 | ? | Oral | II | 15 | 2 | 0 | 2 (13%) | Kuruvilla |
| Everolimus85 | mTOR | Oral | II | 17 | 8 | 1 | 9 (53%) | Johnston |
| Agent . | Target . | route . | Phase . | N . | PR . | CR . | PR + CR . | 1st author . |
|---|---|---|---|---|---|---|---|---|
| HDACs indicates histone deacetylases; mTOR, mammalian target of rapamycin. | ||||||||
| SGN3014 | CD30 | IV | I/II | 15 | 0 | 0 | 0 (0%) | Bartlett |
| MDX06015 | CD30 | IV | II | 47 | 2 | 2 | 4 (8%) | Ansell |
| SGN3521 | CD30 | IV | I (q3 weeks) | 44 | 6 | 11 | 17 (39%) | Younes |
| SGN3522 | CD30 | IV | I (weekly) | 17 | 1 | 7 | 8 (47%) | Bartlett |
| MGCD0103117 | HDACs | Oral | II | 21 | 6 | 2 | 8 (38%) | Younes |
| Panobinostat118 | HDACs | Oral | I | 20 | 8 | 0 | 8 (40%) | DeAngelo |
| Panobinostat70 | HDACs | Oral | II | 27 | 4 | 1 | 5 (18%) | Younes |
| Vorinostat71 | HDACs | Oral | II | 25 | 1 | 0 | 1 (4%) | Kirshbaum |
| Lenalidomide110 | ? | Oral | II | 12 | 3 | 1 | 4 (33%) | Fehniger |
| Lenalidomide111 | ? | Oral | II | 15 | 2 | 0 | 2 (13%) | Kuruvilla |
| Everolimus85 | mTOR | Oral | II | 17 | 8 | 1 | 9 (53%) | Johnston |